Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00992602 : Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer
PhasePhase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Women who are not pregnant (contraception must be used throughout the study)

- Diagnosis of breast cancer with metastases to CNS (regardless of receptor status);
leptomeningeal disease must be present with/without parenchymal brain involvement

- Able to provide informed consent

- No prior treatment with whole brain radiotherapy (WBRT); if patient received
stereotactic radiosurgery (SRS) prior to enrollment it must be well documented which
lesions were treated and untreated index lesions for follow up must be identified; no
treatment with SRS will be permitted while on the study; CNS disease must be
documented by MRI and CSF cytology

- Karnofsky Performance Status > 60

- White blood cells (WBC) >= 3.0 K

- Absolute neutrophil count (ANC) >= 1.5 K

- Platelets (PLT) >= 100 K

- Hematocrit (HCT) >= 30%

- Glomerular filtration rate (GFR) >= 60 mL/min

- Acceptable liver function (see exclusion criteria)

- Any ongoing therapy for systemic disease allows for the addition of systemic HD-MTX
and IT Depocyt; in general patients receiving trastuzumab or lapatinib at the time of
enrollment will be allowed to continue; bisphosphonates (i.e., zoledronic acid) and
denosumab will be allowed; other non-CNS active chemotherapies might be allowed if no
known interactions with study drugs are present; this must be reviewed and approved
by the primary investigator on a case-by-case basis

- Mini-mental state examination score of 24 or above

Exclusion Criteria:

- Serum bilirubin > 1.5 x the upper limit of reference range (ULRR)

- Serum creatinine > 1.5 x ULRR or creatinine clearance =< 60 mL/minute (calculated by
Cockcroft-Gault formula)

- Potassium, < 3.7 mmol/L despite supplementation; serum calcium (ionized or adjusted
for albumin,) or magnesium out of normal range despite supplementation

- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULRR

- Alkaline phosphatase (ALP) > 2.5 x ULRR or > 5 x ULRR if judged by the investigator
to be related to liver metastases

- Evidence of severe or uncontrolled systemic disease or any concurrent condition which
in the investigator's opinion makes it undesirable for the patient to participate in
the trial or which would jeopardize compliance with the protocol

- Patients with known pleural effusion or ascites

- Prior treatment with whole brain radiotherapy (prior treatment with SRS is allowed
under conditions provided in the inclusion criteria)

- Previous allergic or adverse reaction to methotrexate or cytarabine

- Prior treatment with systemic HD-MTX, IT liposomal cytarabine, or IT therapy of any

- Prior IT therapy of any kind

- Women who are currently pregnant or breast feeding

- Previous or current malignancies of other histologies within the last 5 years, with
the exception of cervical carcinoma in situ and adequately treated basal cell or
squamous cell carcinoma of the skin

- Receipt of any investigational agents within 30 days prior to commencing study

- Last dose of prior chemotherapy was less than 4 weeks before the start of study
therapy; patients who had no toxicities with prior chemotherapy can start study
treatment earlier than 4 weeks

- Stereotactic radiosurgery (SRS) less than 2 weeks before the start of study therapy

- Any unresolved toxicity greater than Common Terminology Criteria for Adverse Events
(CTCAE) grade 1 from previous anti-cancer therapy

- Previous enrollment in the present study

- Major surgery within 4 weeks prior to starting therapy, with the exception of the
Ommaya reservoir which can be used for introduction of chemotherapy within 48-72
hours after placement
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557